Sector Gamma AS Has $30.98 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Sector Gamma AS reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 382,362 shares of the biopharmaceutical company’s stock after selling 240,761 shares during the quarter. Gilead Sciences makes up about 7.5% of Sector Gamma AS’s investment portfolio, making the stock its 3rd largest holding. Sector Gamma AS’s holdings in Gilead Sciences were worth $30,975,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Morgan Stanley boosted its position in shares of Gilead Sciences by 0.9% during the third quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock worth $1,267,207,000 after acquiring an additional 158,794 shares during the last quarter. Northern Trust Corp boosted its position in shares of Gilead Sciences by 3.5% during the third quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock worth $1,118,291,000 after acquiring an additional 504,475 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Gilead Sciences by 10.8% during the fourth quarter. Pacer Advisors Inc. now owns 5,046,652 shares of the biopharmaceutical company’s stock worth $408,829,000 after acquiring an additional 493,920 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Gilead Sciences by 12.5% during the third quarter. AQR Capital Management LLC now owns 4,773,688 shares of the biopharmaceutical company’s stock worth $357,740,000 after acquiring an additional 531,314 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of Gilead Sciences by 179.0% during the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after acquiring an additional 2,915,141 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GILD. Barclays decreased their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, February 12th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Wells Fargo & Company reduced their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, UBS Group lowered their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $83.87.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $0.15 during trading hours on Friday, reaching $65.42. 12,382,425 shares of the company’s stock were exchanged, compared to its average volume of 6,443,315. Gilead Sciences, Inc. has a 1 year low of $64.63 and a 1 year high of $87.86. The company has a market capitalization of $81.45 billion, a P/E ratio of 181.72, a price-to-earnings-growth ratio of 1.17 and a beta of 0.19. The business has a fifty day moving average of $71.28 and a two-hundred day moving average of $76.25. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The firm had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same quarter in the prior year, the firm posted $1.37 earnings per share. Gilead Sciences’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, research analysts predict that Gilead Sciences, Inc. will post 4.2 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.